Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Apathy syndrome in a patient previously treated with selective serotonin reuptake inhibitors for depression

  • Kim, Hye-Geum (Department of Psychiatry, Yeungnam University College of Medicine) ;
  • Koo, Bon-Hoon (Department of Psychiatry, Yeungnam University College of Medicine) ;
  • Lee, Seung Woo (Department of Psychiatry, Yeungnam University College of Medicine) ;
  • Cheon, Eun-Jin (Department of Psychiatry, Yeungnam University College of Medicine)
  • Received : 2019.01.25
  • Accepted : 2019.03.06
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

There is considerable overlap in the clinical presentations of apathy and depression. However, differential diagnosis between apathy and other psychiatric conditions, including depression and dementia, is important. In this report, we present the case of a 67-year-old woman with a history of receiving selective serotonin reuptake inhibitor (SSRI) treatment for depression. Differential diagnosis between treatment-resistant depression and SSRI-induced apathy syndrome was required. The symptoms of her apathy syndrome were relieved after the discontinuation of SSRIs and the addition of olanzapine, methylphenidate, and modafinil. Furthermore, we briefly review related literature in this article.

Keywords

References

  1. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3:243-54. https://doi.org/10.1176/jnp.3.3.243
  2. Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract 2004;10:196-9. https://doi.org/10.1097/00131746-200405000-00010
  3. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006;77:8-11. https://doi.org/10.1136/jnnp.2005.069575
  4. Padala PR, Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 2007;41:346-9. https://doi.org/10.1345/aph.1H302
  5. Roth RM, Flashman LA, McAllister TW. Apathy and its treatment. Curr Treat Options Neurol 2007;9:363-70. https://doi.org/10.1007/s11940-007-0022-5
  6. McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C. Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc 2002;8:373-81. https://doi.org/10.1017/S1355617702813182
  7. Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D. Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry 2007;6:7. https://doi.org/10.1186/1744-859X-6-7
  8. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997;7(Suppl 1): S49-55. https://doi.org/10.1016/S0924-977X(97)00419-7
  9. Lanctot KL, Aguera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy associated with neurocognitive disorders: Recent progress and future directions. Alzheimers Dement 2017;13:84-100. https://doi.org/10.1016/j.jalz.2016.05.008
  10. Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997;9:231-9. https://doi.org/10.1176/jnp.9.2.231
  11. van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995;9:49-53. https://doi.org/10.3109/02699059509004571
  12. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995;7:23-30. https://doi.org/10.1176/jnp.7.1.23
  13. Debette S, Kozlowski O, Steinling M, Rousseaux M. Levodopa and bromocriptine in hypoxic brain injury. J Neurol 2002;249:1678-82. https://doi.org/10.1007/s00415-002-0903-1
  14. Newburn G, Newburn D. Selegiline in the management of apathy following traumatic brain injury. Brain Inj 2005;19:149-54. https://doi.org/10.1080/02699050410001719989
  15. Corcoran C, Wong ML, O'Keane V. Bupropion in the management of apathy. J Psychopharmacol 2004;18:133-5. https://doi.org/10.1177/0269881104043284
  16. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-9. https://doi.org/10.1212/01.WNL.0000129990.32253.7B
  17. Zhang N, Wei C, Du H, Shi FD, Cheng Y. The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer's disease patients. Dement Geriatr Cogn Disord 2015;40:85-93. https://doi.org/10.1159/000430808
  18. Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat 2007;3:349-64.
  19. Camargos EF, Quintas JL. Apathy syndrome treated successfully with modafinil. BMJ Case Rep 2011;2011:pii: bcr0820114652.
  20. Marangell LB, Johnson CR, Kertz B, Zboyan HA, Martinez JM. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry 2002;63:391-5. https://doi.org/10.4088/JCP.v63n0503

Cited by

  1. Investigation of the efficiency of various antidepressant replacement regimens in the development of SSRI-induced apathy syndrome vol.12, pp.2, 2020, https://doi.org/10.14412/2074-2711-2020-2-48-56